Jefferies initiated coverage of Gilead (GILD) with a Buy rating and $180 price target The firm calls Gilead “one of the best-positioned large-cap biotechs,” citing the absence of a near-term intellectual property cliff, operating margins on the high end of its biotech/pharma peers and increasing operating leverage as the company builds scale across overlapping franchises.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 8
- Gilead Sciences: Advancing Long-Acting HIV Franchise Underscores Competitive Edge and Supports Buy Rating
- Gilead presents new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data
- Gilead: Strategic Arcellx Acquisition and Anito-cel Pipeline Strength Underpin Buy Rating and $162 Target
- Qualcomm, Booking Holdings upgraded: Wall Street’s top analyst calls